DERM Stock Up 100% After Dermira Announces Positive Trial Results

DERM stock is starting Monday off with a bang. After Dermira, Inc. (NASDAQ:DERM) announced news of a positive trial of dermatitis treatment, shares of the biotech company soared. At the time of writing, DERM stock is up nearly 100%.

DERM Stock Up After Positive Trial Results

On Monday, Dermira, Inc. announced that its phase 2b trial of Lebrikizumab met primary endpoints, resulting in a positive mid-stage trial. Using Lebrikizumab, which is an “injectable, humanized monoclonal antibody,” according to MarketWatch, the trial demonstrated improvements in the EASI score. For perspective, these results are in comparison to a placebo. According to MarketWatch, the study had a sample size of 280 patients.

Investors are pleased with the news, but so is the company itself. According to the study’s lead, Dr. Emma Guttman-Yassky, the data produced in the Dermira phase 2b trial is “compelling.” The data also shows “clinically that IL-13 is a key mediator in atopic dermatitis.” For those who don’t know, immune system cells secrete IL-13, and it is a “central pathogenic mediator in atopic dermatitis,” according to MarketWatch.

>> Gaming Stocks: Turtle Beach Corp Shares Tank After Earnings

DERM Stock Today

As of 11:38 AM, DERM stock is up 98.83%. It is trading at $13.60. DERM stock is fluctuating between 98% and 100% and was up 83% in pre-market trade.

Considering it’s still early in the trading day, it’s possible shares of Dermira could continue to increase, allowing it to end the day a little over 100%. What do you think?

For Those Who Don’t Know

Dermira, Inc. is a biotech company that produces advanced treatments for those suffering from chronic skin conditions, such as hyperhidrosis. The company was founded in 2010 and is based in Menlo Park, California. It has one subsidiary, Valocor Therapeutics, Inc., which develops treatments for dermatological diseases.